Therefore, an accurate assessment of the intra-tumor T cell expression of TIGIT along with that of CD226, which directly competes for the binding to CD155, is critically required at the single patient level to fully take advantage from PARPi-mediated increase in CD155 expression on tumor cells. This evidence concerns the gene CD226 and neoplasm.